Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2019-08, Vol.79 (16), p.4258-4270
Hauptverfasser: Gómez-Miragaya, Jorge, Díaz-Navarro, Ander, Tonda, Raul, Beltran, Sergi, Palomero, Luis, Palafox, Marta, Dobrolecki, Lacey E, Huang, Chen, Vasaikar, Suhas, Zhang, Bing, Wulf, Gerburg M, Collado-Sole, Alejandro, Trinidad, Eva M, Muñoz, Purificación, Paré, Laia, Prat, Aleix, Bruna, Alejandra, Caldas, Carlos, Arribas, Joaquín, Soler-Monso, María Teresa, Petit, Anna, Balmaña, Judith, Cruz, Cristina, Serra, Violeta, Pujana, Miguel Angel, Lewis, Michael T, Puente, Xose S, González-Suárez, Eva
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistance upon continuous drug exposure. Most mutations, small insertions/deletions, and copy number alterations detected in the initial TNBC human metastatic samples were maintained after serial passages in mice and emergence of resistance. We identified a chromosomal amplification of chr12p in a human -mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor. Chr12p amplification was validated in a second pair of docetaxel-sensitive/resistant -mutated PDXs and after short-term docetaxel treatment in several TNBC/ -mutated PDXs and cell lines, as well as during metastatic recurrence in a patient with -mutated breast cancer who had progressed on docetaxel treatment. Analysis of clinical data indicates an association between chr12p amplification and patients with TNBC/basal-like breast cancer, a mutational signature, and poor survival after chemotherapy. Detection of chr12p amplification in a cohort of TNBC PDX models was associated with an improved response to carboplatin. Our findings reveal tumor clonal dynamics during chemotherapy treatments and suggest that a preexisting population harboring chr12p amplification is associated with the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/ -mutated tumors. SIGNIFICANCE: Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/ patients. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/16/4258/F1.large.jpg.
ISSN:0008-5472
1538-7445
1538-7445
DOI:10.1158/0008-5472.CAN-18-3835